Naurex, Inc clinical trials
Acquired by AbbVie, May 8, 2020 · source ↗
The registry lists 20 studies whose lead sponsor is Naurex, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2020.
Before and after it joined AbbVie
- First submitted before Naurex, Inc became part of AbbVie
- 20
- First submitted after Naurex, Inc became part of AbbVie
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Naurex, Inc, an affiliate of Allergan plc20 studies
Something wrong with this grouping? Tell us on the AbbVie page.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. All AbbVie studies →
- Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)TerminatedNCT03614156Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Study of Rapastinel as Monotherapy in Patients With MDDTerminatedNCT03560518Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive DisorderTerminatedNCT03352453Phase 2
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)TerminatedNCT03675776Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)TerminatedNCT03668600Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderCompletedNCT03002077Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive DisorderCompletedNCT02951988Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)CompletedNCT02943564Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Open Label Extension for GLYX13-C-202, NCT01684163TerminatedNCT02192099Phase 2
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)CompletedNCT02943577Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)CompletedNCT02932943Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)WithdrawnNCT03855865Phase 3
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Assessment of Effect of Rapastinel on Driving PerformanceCompletedNCT03814733Phase 1
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Assessment of Abuse Potential of Rapastinel in HumansCompletedNCT03799900Phase 1
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to AntidepressantsCompletedNCT01684163Phase 2
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Study of Intravenous NRX-1074 in Patients With Major Depressive DisorderCompletedNCT02067793Phase 2
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy VolunteersCompletedNCT02366364Phase 1
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal VolunteersCompletedNCT01014650Phase 1
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Safety and Pharmacokinetics of NRX-1074 in Normal VolunteersCompletedNCT01856556Phase 1
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie
- Single IV Dose of GLYX-13 in Patients With Treatment-Resistant DepressionCompletedNCT01234558Phase 2
Sponsor listed in the registry: Naurex, Inc, an affiliate of Allergan plc · First submitted before Naurex, Inc became part of AbbVie